论文部分内容阅读
目的探讨三维适形放射治疗加DLF方案化疗对食管癌的治疗价值。方法 98例食管癌行三维适形放射治疗加DLF方案化疗(综合组)与同期102例单纯三维适形放射治疗(单放组)进行随机对比临床研究。三维适形放射治疗采用6 m V X线常规照射,DT 60~70 GY,分割剂量DT:2 GY,共30~35次。综合组在放射治疗开始前给1周期化疗,放射治疗后每3~4周给1周期化疗,共4~6周期。两组均随访满5年。结果综合组与单放组1、3、5年生存率分别为64.3%、33.7%、19.4%和46.1%、19.6%、12.7%。综合组1、3年生存率明显高于单放组,差异有统计学意义(P<0.05),5年生存率差异无统计学意义(P>0.05),但远地转移率综合组明显低于单放组,差异有统计学意义(P<0.05)。两组治疗中无严重不良反应,均能耐受治疗。结论三维适形放射治疗食管癌加DLF方案化疗是较好值得推广的治疗方法。
Objective To investigate the value of three-dimensional conformal radiotherapy plus DLF regimen in the treatment of esophageal cancer. Methods A total of 98 patients with esophageal cancer undergoing three-dimensional conformal radiotherapy plus DLF regimen (combination group) and 102 cases of simple three-dimensional conformal radiotherapy (single radiotherapy group) were randomized controlled study. Three-dimensional conformal radiotherapy with 6 mV X-ray conventional irradiation, DT 60 ~ 70 GY, split dose DT: 2 GY, a total of 30 to 35 times. The combined group received one cycle of chemotherapy before radiotherapy and one cycle of chemotherapy every 3-4 weeks after radiotherapy for 4 to 6 cycles. Both groups were followed up for 5 years. Results The 1, 3, 5-year survival rates were 64.3%, 33.7%, 19.4% and 46.1%, 19.6% and 12.7% respectively in the combined group and the single group. The 1-year and 3-year survival rates in the integrated group were significantly higher than those in the single group (P <0.05), but there was no significant difference in 5-year survival rates (P> 0.05). However, the distant-metastasis group was significantly lower In the single group, the difference was statistically significant (P <0.05). No serious adverse reactions in the two groups of treatment, can tolerate treatment. Conclusion Three-dimensional conformal radiotherapy esophageal cancer plus DLF regimen chemotherapy is a good treatment worthy of promotion.